Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903658 | 0.91 | LMNA (0.43) | LMNANPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL2898733 | 0.84 | LMNA (0.51) | LMNANPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL2900100 | 0.82 | FGFR1 (0.47) | LMNANPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL3387889 | 0.81 | LMNA (0.50) | LMNANPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL2903706 | 0.78 | SMN1; SMN2 (0.47) | LMNANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL2368911 | 0.78 | LMNA (0.45) | LMNANPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL2899958 | 0.74 | ALDH1A1 (0.51) | LMNANPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL31336915 | 0.74 | ALDH1A1 (0.51) | LMNANPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL2368941 | 0.74 | LMNA (0.43) | LMNANPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL3381246 | 0.74 | LMNA (0.43) | LMNANPC1SMN1; SMN2HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879899-B1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-08-04 | — | — | EP | claimed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | claimed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | claimed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | claimed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | claimed |
| US-8193215-B2 | Thieno[2 3-b]pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| EP-1879899-B1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | XENTION LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | disclosed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | SCN8A, SCN1B, SCN2B | LMNA 2770/4885NPC1 1084/4885SMN1; SMN2 3608/4885 |
| US-20060183768-A1 | Compounds | SCN7A, CBR3, SCN8A | LMNA 2895/4885NPC1 599/4885SMN1; SMN2 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.